|
|
|
|
Pomegranate compounds may help curb breast cancer risk
Researchers have identified chemicals found in the seeds of pomegranates that may reduce the prevalence of a hormone that plays a role in the development of breast cancer.Photograph by: Paula Bronstein / file photo, National Post Enzyme-blocking chemicals in...
|
|
|
Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009
Update on Cardium Therapeutics' plans for commercial development of GenerxCardium Therapeutics reported today that its Cardium Biologics division provided an update on plans ...Teva Pharmaceutical Industries receives FDA tentative approval for generic Femara...
|
|
|
NHS patients losing out as life-saving drugs are sold abroad
'Unscrupulous' pharmacies face closure threat over lucrative export trade in vital medicines Life-saving medicines meant only for sale in the UK are being sold for export at huge mark-ups, causing an acute shortage of drugs that is putting patients' lives at...
|
|
|
Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study
New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumorsNo two tumors are alike, but analyzing the genetics of cancers from different parts of the body may ...Inaugural recipient of the Pfizer/Heart and Stroke Foundation...
|
|
|
Shares of Biotech Stock Cyclacel (CYCC) On the Move
By Paul Ausick, Contributing Editor, InvestorPlace Cyclacel Pharmaceuticals, Inc.(CYCC) announced this morning that a recent study at the University of Texas has shown that its seliciclib drug may potentially treat breast cancer cells that are resistant to...
|
|
|
Cyclacel Presents New Study Data On Seliciclib
Cyclacel Pharmaceuticals said a new study demonstrated that its seliciclib (CYC202 or R-roscovitine), an orally available inhibitor of multiple cyclin-dependent kinases (CDKs), reversed resistance to the aromatase inhibitor letrozole (Femara) and killed...
|
|
|
New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel's Seliciclib in Treating Breast Cancer Resistant to Hormone Therapy
BERKELEY HEIGHTS, N.J., Feb.17, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced that a newly published study demonstrates that the company's seliciclib (CYC202 or R-roscovitine), an orally available...
|
|
|
New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel's Seliciclib in Treating Breast Canc
BERKELEY HEIGHTS, N.J., Feb.17, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced that a newly published study demonstrates that the company's seliciclib (CYC202 or R-roscovitine), an orally available...
|
|
|
New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel's Seliciclib in Treating Breast Cancer Resist
ant to Hormone Therapy Seliciclib Kills Hormone Receptor Positive Breast Cancer Cells Resistant to Letrozole BERKELEY HEIGHTS, N.J., Feb.17, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. today announced that a newly published study demonstrates...
|
|
|
Cyclacel Pharma (CYCC) Publishes Seliciclib Data Regarding Hormone Therapy Resistant Breast Cancer
Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC) today announced that a newly published study demonstrates that the company's seliciclib (CYC202 or R-roscovitine), an orally available inhibitor of multiple cyclin-dependent kinases (CDKs), reversed resistance to...
|
|
|
Approval expanded for breast cancer drug Tykerb
SITE SEARCHWEB SEARCH BY Video Gallery Health More>> MONDAY, Feb.1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast...
|
|
|
Patient's outrage over cancer drug shortage
th February 2010 By By Nicola Fifield A CANCER patient has voiced her anger that she has struggled to get a medicine she needs for her condition because the drug is being sold abroad for greater profit.After The Press reported the plight of Marian Barclay,...
|
|
|
Low-dose estrogen may help if breast cancer recurs
WASHINGTON - A very low dose of estrogen might help women whose breast cancer has come back after treatment, researchers reported Tuesday.Even though most treatments are aimed at stopping estrogen from fueling tumors, the researchers said after years of this...
|
|
|
GSK's Tykerb Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
PHILADELPHIA, Jan.29 /PRNewswire/ -- GlaxoSmithKline ( NYSE:GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment...
|
|
|
US FDA approval for expanded use of GSK's breast cancer drug Tykerb
GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.Tykerb is now...
|
|
|
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer - YAHOO 'undefined' YAHOO.one 'undefined' User?My , 'STREAMER_SERVER' : 'http://streamerapi.finance.yahoo.com','arrowAsChangeSign' : false,...
|
|
|
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer -- PHILADELPHIA, Jan.29 /PRNewswire/ -- Search News Releases WordPress Blog URL: Other News Releases in Other News Releases in Journalists and Bloggers...
|
|
|
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
PHILADELPHIA, Jan.29 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment...
|
|
|
FDA Expands Use of Approved Breast Cancer Drug
Provides oral regime for hormone positive and HER2-positive advanced breast cancer SILVER SPRING, Md., Jan.29 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to...
|
